The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
Competing awards, new and renewals, since FY2014, under this notice and the notices it replaced.
- Past awards
- 2
- 2 new
- Median first-year cost
- $332,249
- $664,497 in all
- Institutions
- 2
- 2 contact PIs
Awards by fiscal year
0
0
2
0
0
0
0
0
0
0
0
0
0
14151617181920212223242526
Fiscal years 2014 to 2026.
Most frequent institutions
- PATH BIOANALYTICS, INC.1
- PROGENRA, INC.1
Most frequent study sections
- Special Emphasis Panel (ZHL1 CSR-I (S1))2
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| FY2016 | In vitro human model for individualized response to CFTR modulators1R41HL130207-01 | Rowe, Steven Mark | PROGENRA, INC., PA | First-year cost $339,094 | Study section ZHL1 |
| FY2016 | Human nasal epithelial organoids as a non-invasive, personalized model for predicting effectiveness of CFTR modulators in cystic fibrosis patients1R41HL130189-01 | Mellnik, John | PATH BIOANALYTICS, INC., NC | First-year cost $325,403 | Study section ZHL1 |
Newest fiscal year first, then first-year cost.
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-13-0.3.2. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.